Decitabine plus busulfan–cyclophosphamide versus busulfan–cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
Decitabine plus busulfan–cyclophosphamide versus busulfan–cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial. // The Lancet Haematology. – URL: https://www.sciencedirect.com/science/article/pii/S2352302626002504?dgcid=rss_sd_all
Decitabine plus busulfan–cyclophosphamide versus busulfan–cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial. The Lancet Haematology. https://www.sciencedirect.com/science/article/pii/S2352302626002504?dgcid=rss_sd_all
“Decitabine plus busulfan–cyclophosphamide versus busulfan–cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial.” The Lancet Haematology.
@article{article68458,
title = {Decitabine plus busulfan–cyclophosphamide versus busulfan–cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial},
journal = {The Lancet Haematology},
url = {https://www.sciencedirect.com/science/article/pii/S2352302626002504?dgcid=rss_sd_all}
}